SEARCH

SEARCH BY CITATION

References

  • 1
    Barrett AJ, Brown MA, Sayers CA. The electrophoretically ‘slow’ and fast forms of alpha 2-macroglobulin molecule. Biochem J 1979; 181: 40118.
  • 2
    Sottrup-Jensen L. α-Macroglobulins: structure, shape, and mechanism of proteinases complex formation. J Biol Chem 1989; 264: 1153942.
  • 3
    Feldman SR, Gonias SL, Pizzo SV. Model of α2-macroglobulin structure and function. Proc Natl Acad Sci USA 1985; 82: 57004.
  • 4
    Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 15160.
  • 5
    Mitchell L, Piovella F, Ofosu F, Andrew M. α-2-Macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children. Blood 1991; 78: 2299304.
  • 6
    Tripodi A, Chantarangkul V, De Stefano V, Mannucci PM. Alpha 2-macroglobulin levels are high in adult patients with congenital antithrombin deficiency. Thromb Res 2000; 98: 11722.
  • 7
    Collen D. Inhibitors of fibrinolysis. In: ThomsonJM, eds. Blood Coagulation and Haemostasis. A Practical Guide, 2nd edn. Edinburgh: Churchill Livingstone, 1980: 26178.
  • 8
    Hermogenes AL, Richardson M, Magalhaes A, Yarleque A, Rodriguez E, Sanchez EF. Interaction of plasminogen activator proteinase, LV-PA with human α2-macroglobulin. Toxicon 2006; 47: 4904.
  • 9
    Deitcher SR, Toombs CF. Non-clinical and clinical characterization of a novel acting thrombolytic: alfimeprase. Pathophysiol Haemost Thromb 2005; 34: 21520.
  • 10
    Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115: 371927.
  • 11
    Tortorella MD, Arner EC, Hills R, Easton A, Korte-Sarfaty J, Fok K, Wittwer AJ, Liu RQ, Malfait AM. α2-Macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes. J Biol Chem 2004; 279: 1755461.
  • 12
    Hoogendoorn H, Toh CH, Nesheim ME, Giles AR. α2-Macroglobulin binds and inhibits activated protein C. Blood 1991; 78: 228390.
  • 13
    Cvirn G, Gallistl S, Muntean W. Effects of α2-macroglobulin and antithrombin on thrombin generation and inhibition in cord and adult plasma. Thromb Res 2001; 101: 18391.
  • 14
    Cvirn G, Gallistl S, Muntean W. Alpha-2-macroglobulin inhibits the anticoagulant action of activated protein C in cord and adult plasma. Haemostasis 2001; 31: 111.
  • 15
    Cvirn G, Gallistl S, Koestenberger M, Kutschera J, Leschnik B, Muntean W. Alpha 2-macroglobulin enhances prothrombin activation and thrombin potential by inhibiting the anticoagulant protein C/protein S system in cord and adult plasma. Thromb Res 2002; 105: 4339.
  • 16
    Marlar RA, Kleiss AJ, Griffin JH. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 1992; 59: 106772.
  • 17
    Elisen MGLM, Von Dem Borne PAK, Bouma BN, Meijers JCM. Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma. Blood 1998; 91: 15427.
  • 18
    Nowak-Göttl U, Junker R, Hartmeier M, Koch HG, Münchow N, Assmann G, Eckardstein von A. Increased lipoprotein (a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999; 100: 7438.
  • 19
    Kreuz W, Stoll M, Junker R, Heinecke A, Schobess R, Kurnik K, Kelsch R, Nowak-Göttl U. Familial elevated factor VIII in children with symptomatic venous thrombosis and postthrombotic syndrome. Results of a multicentre study. Arterioscler Thromb Vasc Biol 2006; 26: 19016.
  • 20
    Junker R, Koch HG, Auberger K, Münchow N, Ehrenforth S, Nowak-Göttl U. Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. Arterioscler Thromb Vasc Biol 1999; 19: 256872.
  • 21
    Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80: 19982005.
  • 22
    Ehrenforth S, Junker R, Koch HG, Kreuz W, Münchow N, Scharrer I, Nowak-Göttl U. Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Eur J Pediatr 1999; 158: S97104.
  • 23
    Fletcher AP, Alkjaersig N, Davies A, Lewis M, Brooks J, Hardin W, Landau W, Raichle ME. Blood coagulation and plasma fibrinolytic enzyme system pathophysiology in stroke. Stroke 1976; 4: 33748.
  • 24
    Picard V, Nowak-Göttl U, Biron-Andreani C, Fouassier M, Frere C, Goualt-Heilman M, De Maistre E, Regina S, Rugeri L, Ternisien C, Trichet C, Vergnes C, Aiach M, Alhenc-Gelas M. Molecular bases of antithrombin deficiency: twenty-two novel mutations in the antithrombin gene. Hum Mutat 2006; 27: 6006.
  • 25
    Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995; 74: 41525.
  • 26
    Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, Bernstein M, Brisson L, Cairney B, DeSai D, Grant R, Israels S, Jardine L, Luke B, Massicotte P, Silva M. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian registry of VTE. Blood 1994; 83: 12517.
  • 27
    Van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001; 139: 67681.
  • 28
    Revel-Vilk S, Chan A, Bauman M, Massicotte P. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost 2003; 1: 91521.
  • 29
    Hathaway WE. Clinical aspects of antithrombin III deficiency. Sem Hematol 1991; 28: 1923.